Abstract and Introduction
Introduction
Neuropathic pain (NP) is caused by lesions or diseases of the somatosensory system. [1] The site of disturbance or damage can be peripheral (peripheral nerve, plexus, or root) or central (spinal cord, brainstem, or thalamus). The pain often has burning, jabbing, and searing quality. Areas of skin allodynia (touch perceived as pain), hyperalgesia (enhanced pain after exposure to painful stimuli), and hyperesthesia or dysesthesia (enhanced or altered sensations to touch) are commonly observed.
The pathophysiology of neuropathic pain is yet to be fully explored; peripheral neuropathic pain (PNP) is believed to result from damage to the peripheral nervous system leading to irritation of nerve endings and accumulation of nociceptive transmitters and modulators (substance P, glutamate, bradykinin, calcitonin gene-related peptide [CGRP] , and others). Focal inflammation follows local accumulation of these agents. Together, these two phenomena lower the sensory threshold of peripheral nerve endings to nociceptive stimuli (peripheral sensitization). Peripheral sensitization increases the number of nociceptive volleys into the spinal cord and leads to sensitization of sensory spinal cord neurons (central sensitization). Sustained peripheral and central sensitization leads to pain chronicity. [2] The pharmaceutical agents which improve neuropathic pain modify one or more of these mechanisms.
Botulinum neurotoxins can alter and alleviate neuropathic pain in animals through several mechanisms ( Fig. 1 ): blocking release of pain mediators (glutamate, substance P, CRGP) from peripheral terminals, dorsal root ganglia (DRG), and spinal cord neurons; [3] [4] [5] decreasing local inflammation around nerve terminals; [6] deactivation sodium channels; [7, 8] inhibiting discharge of muscle spindles; [9] and decreasing sympathetic transmission. [10] The latter two mechanisms can enhance central sensitization. Seven examples of peripheral neuropathic pain (PNP) for which prospective and controlled data are available on BoNT efficacy are discussed in this review article. These include postherpetic neuralgia, posttraumatic neuralgia, trigeminal neuralgia (TN), painful diabetic neuropathy (PDN), complex regional pain syndrome, residual limb pain, and phantom pain. Case reports are provided based on our clinical experiences. In this review, the level of efficacy for BoNTs is defined according to the guidelines of the Therapeutics and Assessment Subcommittee of the American Academy of Neurology (AAN). [11] According to these guidelines, level A evidence (effective or not effective) requires two class I studies.
Botulinum Toxin Treatment of Neuropathic Pain
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In the onaBoNT-A group, the toxin was diluted with 4 cc of normal saline and injected subcutaneously via a 30-gauge needle in a "chessboard manner." The dose per injection site was 5 U. A total of 100 U was used. The severity of pain was assessed by VAS (0-10) at baseline, and then daily for the first 2 weeks, every 2 weeks until the 12th week, and every 4 weeks until the 24th week. The primary outcome was 50% or more reduction in the VAS score measured at week 4 compared with baseline. The secondary outcome was improvement in quality of sleep evaluated by a 5-point questionnaire (very bad to very good) recorded at the same time frames. Maintenance of improved VAS scores beyond the first 4 weeks was also considered a secondary outcome. Significant VAS improvement was reported at 4 weeks and also over subsequent weeks (for the toxin group, p < 0.001). Patients in the BoNT group also demonstrated significant improvement in quality of sleep and reduction of sleep scores along the same timelines.
Retrospective observations in small numbers of patients reported significant pain relief after BoNT administration in patients with PHN, supporting blinded observations. [27, 28] Lastly, the controlled and blinded study by Ranoux et al, [29] which demonstrated efficacy of onaBoNT-A in neuropathic pain (rated class I by AAN subcommittee), also included four patients with PHN. The specifics of these four patients, however, were not provided.
Case Report
A 62-year-old woman was referred to the Yale Botulinum Toxin Treatment Clinic for management of severe pain behind the right ear. Pain started 2 years ago, and at the onset affected both the inside and behind the right ear. A course of antibiotics was not helpful. A few weeks later, typical skin lesions of zoster infection appeared. Treatment with acyclovir gradually improved the skin lesions, but the right retroauricular pain continued to grow in intensity. Some of the severe bouts of pain ended in disabling headaches. The pain, which was described as jabbing and stabbing, resulted in loss of sleep and marked apprehension in anticipation of the next bout. A variety of analgesic medications including gabapentin, pregabalin, and oxycodone were not helpful. The pain was often scored as 10 of 10 on the VAS, and described as "unbearable."
On examination, residual scars of zoster infection were seen behind the right ear. A total of 60 U of onaBoNT-A was injected in a grid-like pattern behind the right ear subcutaneously at 20 points (3 U/point) using a 30-gauge needle ( increased density of sodium channels, [30] which, via increased nociceptive excitability, generate ectopic discharges. New sprouts show increased sensitivity to cytokines, prostaglandins, and catecholamines. This peripheral sensitization increases the volume of nociceptive volleys that enter the dorsal root ganglia and spinal cord. Histologic changes that develop after peripheral trauma in the DRG and spinal cord indicate increased neural excitation. In DRG, there is overgrowth of sympathetic nerves and abnormal linkage of A and C fibers. [31] In the spinal cord, dark cells appear in dorsal horns which presumably represent dying inhibitory neurons of glycinergic and GABAergic types. [32, 33] Demise of inhibitory neurons leads to enhanced excitation of central neurons. It has also been shown that after peripheral injury, many large α/beta afferents (usually ending in Rexed area III) grow and penetrate more superficial levels (Rexed lamina II and I of the dorsal horn) and gain access to low threshold, pain afferents. [34] 
Treatment
Medical treatment consists mostly of administration of analgesic agents defined under the postherpetic neuralgia section above. Additional treatments include nerve block by single injection or infusion, transcutaneous electrical nerve stimulation, peripheral nerve stimulation, or spinal cord (dorsal horn) stimulation, which increases GABA release.
BoNT Treatment of Posttraumatic Neuralgia. Ranoux et al [29] screened 61 consecutive patients; 29 met the criteria of neuropathic pain and eligibility for BoNT treatment. Nineteen were women. Twenty-five patients had posttraumatic neuralgia; four patients had postherpetic neuralgia. In the posttraumatic group, 18 patients had surgical trauma and 7 patients had nonsurgical trauma to single nerves. The patients were enrolled in a OnabotulinumtoxinA was injected subcutaneously into the dorsolateral aspect of the right foot (50 U, 20 sites, grid pattern) including the region of lateral malleolus. The patient reported a 30% reduction of her pain (VAS level 7) after the first injection, and a 90% decrease after the second injection (VAS level 1-2) 6 months later; in the patient's words, "the effect after the second injection was astounding. I stopped taking gabapentin and using pain wraps at night. I can now wear boots for the first time in 12 years!" An examination 3 months after the second injection showed marked reduction of allodynia, which was now limited to a small area above the lateral malleolus. Over the next 3 years, the patient received similar injections every 6 to 9 months. When the pain returned, the intensity remained low, and for the most part, tolerable (VAS level 2-3).
Comment. The level of evidence for efficacy of onaBoNT-A for PTN is B (probably effective) based on one class I study. The case presented above is an example of PTN with severe allodynia showing a remarkable response to onaBoNT-A after two treatments. Some patients with PTN may later develop complex regional pain syndrome (CRPS), a condition that is more difficult to treat. An important question is if early treatment of PTN with a
BoNTs can prevent development of CRPS.
Trigeminal Neuralgia
Trigeminal neuralgia (TN) is one of the most painful of human afflictions with a peak age of 50 to 70 years and an incidence of 4 in 100,000 in the United States. [35, 36] The pain is severe, often described as jabbing, stabbing, and shock-like, usually affecting one side of the face. The typical pain of TN lasts seconds, but durations of up to 2 minutes have also been observed. Bouts of pain may occur multiple times a day and disable the patient.
Facial movements, eating, speaking, chewing, and shaving often exacerbate the pain. Many patients have local trigger points in the face that upon touching provoke severe pain. Antiepileptic drugs such as carbamazepine, oxcarbazepine, gabapentin, and GABAergic medications such as baclofen (30-60 mg), which enhances inhibitory mechanisms, may provide relief. In one blinded study, the combination of carbamazepine and baclofen proved more effective, than either of the two alone. [37] Unfortunately, pharmacological failures are not uncommon. In recalcitrant cases, surgical decompression and Gamma Knife surgery may alleviate the pain. [38] Both approaches are not devoid of side effects, which may be substantial and include ataxia, brainstem damage, and cranial nerve palsies.
Pathophysiology
Major pain mediators, specific pain receptors, and a pain-activating voltage-gated sodium channel are highly expressed in the neurons of trigeminal ganglia and at trigeminal nerve endings. Cultured trigeminal neurons, within days, release large amounts of CGRP, a major inflammatory pain mediator. [39] Also, the role of endothelin (A and B) has been investigated as pronociceptive in the trigeminal system. [40] The data from cell culture and animal studies explain some of the mechanisms through which administration of BoNTs relieves pain in TN. Addition of onaBoNT-A (BOTOX) to the cultured trigeminal neurons results in a marked reduction of CGRP release from stimulated trigeminal neurons. [39] In an acute infraorbital nerve injury model that causes significant local allodynia in the rat, subcutaneous injection of onaBoNT-A improved allodynia and reduced release of pain mediators from disconnected trigeminal neurons. [41] Transient receptor potential vanilloid 1 (TRPV1), a cation channel, which promotes the release of CGRP, is highly expressed in a large number of trigeminal neurons. Addition of A/E chimera of BoNT (which specifically targets sensory neurons) to the trigeminal cell culture inhibits the release of CGRP secondary to activation of TRPV1. [42] Furthermore, subcutaneous injection of 0.25 and 0.5 ng/kg of onaBoNT-A into a rat's face markedly reduced the expression of TRPV1 in the trigeminal neurons within 2 days. [43] Matak et al [44] maintain that the analgesic effect of the BoNT-A in experimental TN of rats (formalin injection into the whiskers) results in a large part from a direct central effect of the toxin. In this model, after BoNT-A administration, the authors detected the presence of truncated SNAP25 in the sensory trigeminal nucleus in the medulla. The analgesic effect of the toxin was blocked by injection of colchicine into the trigeminal ganglia, which blocks and prevents the toxin from reaching the central nervous system.
Botulinum Toxin Treatment of Trigeminal Neuralgia
Twenty reports have described the effect of BoNT treatment on TN. All described favorable effects and no serious side effects. Three studies were double blind, [45] [46] [47] one single blind and prospective, [48] and others were retrospective. Long-term effect was assessed in one retrospective study beyond one year. [49] Wu et al [45] enrolled 42 patients with TN in a 13-week, randomized, parallel design, double-blind, placebo controlled study. BoNT group compared with the placebo group (p < 0.001). Side effects were noted in the subjects who received BoNT; seven subjects developed mild facial asymmetry, which disappeared after 7 weeks, and three developed local facial swelling, which subsided in a week. Two years later, the same group of authors [46] conducted another blinded study in TN comparing specifically the effect of 25 U versus 75 U of BoNT-A compared with placebo. Both doses significantly reduced the pain as early as week 1, and the effect was sustained until week 8 throughout the study. There was no significant difference in efficacy between the two dose groups. The PGIC was significantly better in the treatment groups (67% in the 25 U group and 76% in the 75 U group compared with 32% in the placebo group). Authors concluded that the low dose of 25 U was sufficient to improve the pain of TN. Higher doses are not necessarily better and could cause more side effects (facial weakness). Zuniga et al [47] conducted a double-blind, randomized, placebo-controlled study in which 20 patients received onaBoNT-A and 16 patients received placebo. Patients received 50 U of onaBoNT-A subcutaneously, and an extra 10 U of intramuscular onaBoNT-A in the masseter muscle if there was involvement of mandibular branch of trigeminal nerve. At 2 months, the mean VAS showed a trend toward improvement in the onaBoNT-A group compared with the placebo group (p = 0.07). At 3 months after the injection, significant improvement in the VAS was seen in the onaBoNT-A group (p = 0.01).
In the single blind study of Shehata et al, [48] 20 subjects with TN were randomized into BoNT and placebo groups. In the BoNT group, subjects received subcutaneous injections of 40 to 60 U of onaBoNT-A into 8 to 12 points (5 U per point) in the face. Primary outcome was a decrease in pain intensity at 12 weeks, measured by the VAS, compared with the placebo. At 12 weeks, the onaBoNT-A group demonstrated a reduction of 6.5 points on the VAS, compared with 3 points in the placebo group (p = 0.0001). As a secondary outcome, quality of life also improved significantly, and more patients in the BoNT group were able to reduce the number of pain medications needed. In a recent longitudinal study of 87 patients who received repeated injections of BoNT for TN for 14 months, patients had significant relief, with overall improvement in anxiety, depression, and sleep, and improved quality of life. [50] Case Report She reported several trigger points close to the nose and corner of the mouth, making application of makeup difficult. During "bad days," the pain affected the region around the left eye and made it "twitch."
The patient had tried multiple medications for the pain, including β-blockers, antiepileptic drugs, calcium channel blockers, nonsteroidal anti-inflammatory drugs, oxycodone, and acupuncture. She had undergone three surgical procedures in the past: decompression surgery via retromastoid craniotomy for relieving pressure over the trigeminal nerve, exploration for possible cerebellum-pontine angle pathology, and cortical stimulation for pain relief. None of the three procedures relieved her pain. The patient described constant daily background facial pain with superimposed bouts of sharp pain.
On examination, several trigger points were identified on the left side of the face close to the nose and corner of the mouth. A total of 30 U of onaBoNT-A was injected subcutaneously in 20 sites (1.5 U per site) in the V2 distribution. In addition, another 10 U (four points) were injected into the left frontalis (2.5 U, four sites) and 5 U into the anterior temporal region (2.5 U, two points).
After 2 weeks, the patient reported marked reduction in the severity of pain (from level 9 in the VAS to 2) and in the frequency of sharp pains (90% less). This response lasted for 5 months, at which time the severity of pain returned and required another injection that produced a similar effect. No side effects were reported. The patient described her experience as very satisfactory in PGIC. Five of the six patients reported significant pain relief. Only one developed mild transient facial weakness.
Complex Regional Pain Syndrome
Complex regional pain syndrome (CRPS) often evolves from posttraumatic neuralgia. For reasons that are yet poorly understood, a traumatized limb affected by somatic pain gradually develops additional autonomic and trophic dysfunction. In CRPS I, the causative factor does not damage or disrupt the nerve, whereas in CRPS II, the peripheral nerve is damaged. Causalgia, first described in detail by Weir Mitchell among soldiers with traumatized limbs during the American Civil War, belongs to the CRPS II category. [51] Pain in CRPS has a burning and jabbing quality, and the involved limb has areas of allodynia and hyperesthesia. Autonomic dysfunction can be in the form of coldness or warmth of the limb with hyper-or hypohidrosis.
Trophic changes include skin atrophy, hair loss, and nail changes. [52] Motor symptoms such as finger, hand, and arm dystonia and tremor may develop and cause further discomfort. Symptoms may progress proximally and result in pain and dystonia of the arm and shoulder muscles. In severe cases, loss of vascular supply can threaten the development of gangrene and may necessitate limb amputation.
http://www.medscape.com/viewarticle/859139_print 9 of 16 4/25/16 9:14 PM
Pathophysiology
For years, primary dysfunction of the sympathetic system was held responsible for the development of CRPS. This view is now modified in favor of neuroinflammation and deranged autoimmunity, with small C fiber damage playing a pivotal role. Damage to C-fibers could lead to neurogenic inflammation, ectopic firing, vasodilation (via axon reflex), and/or hypoxic/ischemic injury. [53, 54] Evidence exists that neural inflammation extends to the spinal cord in some patients. In one patient with longstanding CRPS, tissue examination of the dorsal horn demonstrated significant activation of microglia and astrocytes with neuronal loss. [55] 
Conventional Treatment
Treatment of CRPS is difficult and geared to relief of pain and modification of the course of the disease. Treatment of pain with tricyclic antidepressants, calcium channel blockers, gabapentin and pregabalin, serotonin/norepinephrine reuptake inhibitors, and locally delivered anesthetics is partially effective. Intranasal calcitonin (100-400 U) may relieve pain in some patients. In a blinded study, intravenous infusion of ketamine (N-methyl-D-aspartate antagonist) effectively reduced pain in 16 of 20 patients, with follow-up of 6 months. [56] However, the recommended dose of 100 mg for 4 h/d for 10 days can be associated with significant hepatotoxicity requiring close liver function monitoring. Recently, a small double-blind crossover study of 12 patients suggested the efficacy of intravenous immunoglobulin. [57] In general, CRPS is considered a very difficult condition to treat.
BoNT Treatment of CRPS
Argoff et al [58] reported alleviation of pain, skin color, and local edema in 11 patients with CRPS following intramuscular injection of onaBoNT-A. In agreement with this observation, a single case report described marked reduction of allodynia after subcutaneous injection of onaBoNT-A in a patient with CRPS and dorsal hand allodynia. [59] In contrast, in a blinded, controlled, parallel study, Safarpour et al [60] found no statistically significant difference between onaBoNT-A and placebo in eight patients with severe CPRS allodynia. The authors also reported failure of onaBoNT-A in an open trial of an additional six CRPS patients. In another publication, however, the same authors reported significant improvement of proximal pain, proximal and distal dystonia, and shooting arm pain in two patients with CPRS after intramuscular injection of onaBoNT-A into painful proximal muscles (deltoid, trapezius, levator scapulae, supraspinatus, upper thoracic paraspinal, and flexor digitorum superficialis). The total injected dose was 300 U. [61] In one of these patients, concurrent exquisite dorsal hand allodynia also gradually improved after 2 years of repeated proximal intramuscular injections. A retrospective report of 37 patients by Kharkar et al [62] also indicated improvement of CRPS after intramuscular injection of shoulder girdle muscles.
Comment
The natural history of CPRS reflects a debilitating condition with poor prognosis. One long-term follow-up study found little improvement of symptoms with current methods of treatment. [56] The role of BoNT treatment in CRPS is evolving and at this point, the level of efficacy is U (undetermined) due to lack of class I and II studies. The encouraging reports of open observations need to be examined by larger controlled studies. On the technical side, patients with severe allodynia (advanced CRPS) tolerate injections poorly. Three important questions to be addressed in future studies are Is a combined subcutaneous and intramuscular injection more effective than subcutaneous or intradermal injection alone? 1.
Can early and aggressive treatment with BoNTs slow down the dismal course of CRPS? 2.
Are proximal injections combined with distal injections more effective than distal injections alone? 3.
Metabolic and Drug-induced Painful Peripheral Neuropathies
A large number of metabolic derangements and medications affect the peripheral nerves. In some, pain is a major symptom. The focus of this section is on PDN, the only metabolic neuropathy for which blinded, placebo controlled clinical trial results with BoNT treatment is available. No blinded data on BoNT treatment of drug-induced peripheral neuropathies are available.
Diabetic Neuropathy
Among metabolic disorders, DN can be considered a model of metabolic neuropathic pain. Painful neuropathy is more common in type 2 diabetes, with a prevalence of 25 to 26% versus the 16% reported for type 1 diabetes among younger individuals. [63, 64] The persistent pain often has a burning and aching quality. Examination shows reduced or lost sensory modalities consistent with DN, but also areas of hyperesthesia and allodynia. Chronic pain causes anxiety and depression, impairing quality of life due to psychosocial distress and disrupted sleep.
Pathophysiology. For many years, hyperglycemia was considered the reason for the development of pain in DPN. Recent data suggest hypoinsulinism and abnormal insulin signaling as a more relevant factor. [65] At the molecular level, sodium channels, nonselective calcium channels http://www.medscape.com/viewarticle/859139_print 10 of 16 4/25/16 9:14 PM linked to transient receptor potential receptor (TRP), and receptors for nerve growth factors are all expressed highly in DRG neurons and are believed to have a role in the pain of DN. More recently, evidence for the role of CaV3.2 T-type voltage-gated calcium channels (T-channels) in PDN has been emphasized. [66] Treatment of Painful Diabetic Neuropathy. The treatment strategy focuses on modifying the mechanisms that cause neuropathic pain. As per the AAN guidelines, pregabalin is effective in PDN (level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone), and capsaicin are probably effective for PDN (level B). [67] A palliative role for erythropoietin analogues, angiotensin II type 2 receptor, voltage-gated sodium channel antagonists, and lipo-prostaglandin E3 agents has been suggested by earlier observations, and is now further explored by blinded studies. [7, 68, 69] BoNT Treatment in Diabetic Neuropathy. Two placebo controlled, blinded studies have investigated the efficacy of onaBoNT-A (BOTOX) in PDN.
Yuan et al [70] conducted a double-blind crossover study in 18 patients, injecting onaBoNT-A or saline intradermally into the hyperesthetic and allodynic foot regions (4 U/site in the case of onaBoNT-A). The pain reduction, measured by VAS, was significant in favor of onaBoNT-A at 1, 4, 8, and 12 weeks (p < 0.05). OnabotulinumtoxinA administration improved sleep at one week (using the Chinese version of the Pittsburg Sleep Quality Index [CPSQI]; p < 0.05). Quality of life assessed by SF36 also improved in more patients in the onaBoNT-A group (compared with placebo), but the difference was not statistically significant.
Chen et al [71] conducted a blinded, placebo controlled crossover study and assessed the efficacy of onaBoNT-A in 18 patients with PDN. 
Comment
Controlled studies are needed for assessment of the efficacy and utility of BoNT treatment in painful neuropathy related to chemotherapeutic agents.
Such patients are often on polypharmacy, which makes introduction of additional pain medications unwelcome.
Residual Limb Pain and Phantom Pain
With an increasing frequency of military conflicts, pain associated with loss of limb has become a major medical management issue among soldiers.
It is predicted that in the United States, the number of patients affected by this type of pain will exceed 3 million by the year 2050. incidence of RLP after amputation is 22% to 43%, and for PLP 66%. [73, 74] The possible mechanism and pathophysiology of phantom pain is discussed in detail in a recent review. [75] Pharmacological Treatment A Cochrane review of the literature [76] concluded that, based on blinded studies, morphine, gabapentin, and ketamine demonstrate a trend toward short-term analgesic efficacy in PLP, while memantine and amitriptyline were ineffective. No data on long-term efficacy are available. The role of calcitonin, anesthetics, and dextromethorphan requires further clarification. In clinical practice, gabapentin is now used increasingly as the first drug of choice for the treatment of PLP due to its safer side-effect profile. Because long-term efficacy of drugs against PLP is low (less than 5% in one large review), [77] exploration of novel therapeutic approaches is urgently needed.
BoNT Treatment of RLP and PLP
Two clinical observations, each on a small number of patients, claimed BoNT administration into stump muscles improves phantom pain. In one study, [78] four patients were injected with 2,500 to 5,000 U of rimabotulinum toxin type B (MYOBLOC) into the arm and leg stumps (two patients each). Injections were performed at multiple trigger points. All patients reported improvement in stump pain, PLP attacks, and improvement of local http://www.medscape.com/viewarticle/859139_print
11 of 16 4/25/16 9:14 PM allodynia. One patient noted significant improvement of sleep. Improvements lasted for "many weeks." In one patient, a 12-month follow-up showed almost total pain relief. In another study, [79] authors described significant improvement of phantom pain in three patients (two with accidental injury and one with a landmine injury) after electromyogram-guided administration of abobotulinumtoxinA (up to 500 U) into the stump muscles. All three patients reported level 3 (on a 0-3 scale) improvement on the Clinical Global Assessment Scale, as well as substantial pain improvement on the VAS. Pain improvement lasted 11 months. Patients were able to reduce their pain medications after BoNT treatment.
Unfortunately, these positive observations did not bear out in a recent prospective, parallel design, blinded study (class III, no placebo), which compared the effect of onaBoNT-A with that of combined lidocaine/methylprednisolone therapy. [80] Investigators injected 250 to 300 U of onaBoNT-A or 10 mg Depo-Medrol in 1% lidocaine in up to six tender points of 14 patients with RLP and PLP. There was no significant effect on phantom pain from either of the two agents. Both agents, however, significantly improved RLP and pain tolerance. Effect of onaBoNT-A on RLP and pain tolerability was stronger than that of the lidocaine/Depo-Medrol injection (p = 0.002 vs. p = 0.06 and p = 0.01 vs. 0.07, respectively). The relief of RLP in both groups lasted for 6 months. 
